Plunkett Research Online: 89bio Inc

89BIO INC (ETNB) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue. The fibroblast .....


89BIO INC

Ticker: ETNB
Exchange: NAS
Parent Company:
Employees:
Fiscal Year Ends in

Phone: 415 500-4614
Fax:
Address: 142 Sansome Street
San Francisco, CA 94104 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Contacts Description

Rohan PalekarCEO/Director
Ryan MartinsCFO/Chief Accounting Officer
See More
89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue. The fibroblast .....See More See More

$USD, In whole numbers2023202220212020201920182017
Sales
Profits
Brands, Divisions and Affiliates Top Salaries
Salary
Bonus
Other Thoughts Corporate Culture